Mapi advances on GA Depot

No immediate post-injection reactions, “as are frequently seen with Copaxone and generic glatiramer acetate”, were detected in a Phase II study for the long-acting glatiramer acetate product that Mylan is developing with Mapi Pharma (Generics bulletin, 13 April 2018, page 12). Presenting two-year clinical data from the Phase II study of its ‘GA Depot’ candidate at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Mapi said that with all participants receiving a 40mg dose of GA Depot once every four weeks, “the number of adverse events (AEs) was considerably reduced during the second year of treatment compared with the first year”.